U
Ustekinumab [Ichalig]
Availability of ACE Drug Guidance
Yes
Biologics Drug Information Overview
No
Subsidy Information and Financing Scheme
No
Active ingredient: Ustekinumab
General information
Subsidy Information and Financing Scheme
Not Applicable
Drug Guidance for Subsidy
06/02/2026 Ustekinumab biosimilar for treating inflammatory conditions
The Ministry of Health’s Drug Advisory Committee has recommended ustekinumab biosimilar (Steqeyma) 45 mg/0.5 mL pre-filled syringe, 90 mg/1 mL pre-filled syringe, and 130 mg/26 mL vial for listing on the MOH Standard Drug List (SDL). The decision was based on the acceptable pricing proposal from the company.
Funding status
[R] SDL subsidy will apply from 1 April 2026 to all registered indications of ustekinumab biosimilar (Steqeyma) 45 mg/0.5 mL pre-filled syringe, 90 mg/1 mL pre-filled syringe, and 130 mg/26 mL vial in Singapore.
[NR] SDL subsidy does not apply to other brand(s), formulation(s) or strength(s) of ustekinumab.
Registered Product(s) Information
Clinical and product info
Clinical info | Product Info |
|---|---|
Information under the Indication, Dosage and Contraindication sections are extracted from the relevant Package Insert/Patient Information Leaflet of the product available on HSA Infosearch. For more information, please refer to the product's Package Insert/ Patient Information Leaflet available on HSA Infosearch. The information provided is for informational purposes only, and is not exhaustive. The information provided is not a substitute for professional medical advice. Please consult a qualified healthcare provider for any medical advice. | Information available here are product details as registered with the HSA. As this website is updated monthly, please refer to HSA Infosearch for the most updated product information. |
Subcutaneous
* Clinical information is available for this product.